• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Biomarker microfibril-associated glycoprotein 4 for non-invasive diagnosis and therapeutic evaluation of hepatic fibrosis in patients with hepatitis C.

作者信息

Eom Young Woo, Baik Soon Koo

机构信息

Cell Therapy and Tissue Engineering Center, Yonsei University Wonju College of Medicine, Wonju, Korea.

Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.

出版信息

Clin Mol Hepatol. 2019 Mar;25(1):37-39. doi: 10.3350/cmh.2018.1011. Epub 2018 Dec 11.

DOI:10.3350/cmh.2018.1011
PMID:30531664
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6435975/
Abstract
摘要

相似文献

1
Biomarker microfibril-associated glycoprotein 4 for non-invasive diagnosis and therapeutic evaluation of hepatic fibrosis in patients with hepatitis C.生物标志物微原纤维相关糖蛋白4用于丙型肝炎患者肝纤维化的无创诊断和治疗评估
Clin Mol Hepatol. 2019 Mar;25(1):37-39. doi: 10.3350/cmh.2018.1011. Epub 2018 Dec 11.
2
Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients.基于直接作用抗病毒药物的治疗可降低丙型肝炎患者肝纤维化血清生物标志物微纤维相关蛋白 4。
Clin Mol Hepatol. 2019 Mar;25(1):42-51. doi: 10.3350/cmh.2018.0029. Epub 2018 Nov 19.
3
Analysis of disease-associated protein expression using quantitative proteomics—fibulin-5 is expressed in association with hepatic fibrosis.使用定量蛋白质组学分析疾病相关蛋白表达——纤连蛋白-5与肝纤维化相关表达。
J Proteome Res. 2015 May 1;14(5):2278-86. doi: 10.1021/acs.jproteome.5b00053. Epub 2015 Apr 6.
4
Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C.评估慢性丙型肝炎患者抗病毒治疗前后不同血清标志物组合对肝纤维化的影响。
Aliment Pharmacol Ther. 2011 Jan;33(1):138-48. doi: 10.1111/j.1365-2036.2010.04500.x. Epub 2010 Oct 26.
5
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial.丙型肝炎中的肝脂肪变性：丙型肝炎抗病毒长期治疗预防肝硬化试验中糖尿病与非糖尿病患者的比较
Clin Gastroenterol Hepatol. 2007 Feb;5(2):245-54. doi: 10.1016/j.cgh.2006.11.002.
6
Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis.目前处于治疗丙型肝炎病毒相关肝纤维化早期研发阶段的药物。
Expert Opin Investig Drugs. 2015;24(9):1229-39. doi: 10.1517/13543784.2015.1057568. Epub 2015 Jun 30.
7
Hepatitis C virus infection in children in the era of direct-acting antiviral.直接作用抗病毒药物时代儿童丙型肝炎病毒感染
World J Gastroenterol. 2018 Jun 28;24(24):2555-2566. doi: 10.3748/wjg.v24.i24.2555.
8
Combined antiretroviral therapy attenuates hepatic extracellular matrix remodeling in HIV patients assessed by novel protein fingerprint markers.通过新型蛋白质指纹标记物评估发现，联合抗逆转录病毒疗法可减轻HIV患者肝脏细胞外基质重塑。
AIDS. 2014 Sep 10;28(14):2081-90. doi: 10.1097/QAD.0000000000000388.
9
IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection.IP-10与丙型肝炎病毒载量、肝脏炎症及纤维化相关，并可预测HIV-HCV合并感染中丙型肝炎病毒的复发或无应答情况。
Antivir Ther. 2008;13(8):969-76.
10
MFAP4: a candidate biomarker for hepatic and pulmonary fibrosis?MFAP4：肝脏和肺纤维化的候选生物标志物？
Sarcoidosis Vasc Diffuse Lung Dis. 2016 Mar 29;33(1):41-50.

引用本文的文献

1
A Proteomic Study of Atherosclerotic Plaques in Men with Coronary Atherosclerosis.一项关于患有冠状动脉粥样硬化男性的动脉粥样硬化斑块的蛋白质组学研究。
Diagnostics (Basel). 2019 Nov 7;9(4):177. doi: 10.3390/diagnostics9040177.

本文引用的文献

1
Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients.基于直接作用抗病毒药物的治疗可降低丙型肝炎患者肝纤维化血清生物标志物微纤维相关蛋白 4。
Clin Mol Hepatol. 2019 Mar;25(1):42-51. doi: 10.3350/cmh.2018.0029. Epub 2018 Nov 19.
2
Non invasive tools for the diagnosis of liver cirrhosis.用于诊断肝硬化的非侵入性工具。
World J Gastroenterol. 2014 Dec 28;20(48):18131-50. doi: 10.3748/wjg.v20.i48.18131.
3
Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: the Boston children's hospital experience.血清生物标志物和瞬时弹性成像在美国队列中预测晚期肝纤维化的价值：波士顿儿童医院的经验。
J Pediatr. 2013 Oct;163(4):1058-64.e2. doi: 10.1016/j.jpeds.2013.04.044. Epub 2013 Jun 5.
4
Combining transient elastography with FIB4 enhances sensitivity in detecting advanced fibrosis of the liver.将瞬时弹性成像与FIB4相结合可提高检测肝脏晚期纤维化的敏感性。
Scand J Gastroenterol. 2013 Jan;48(1):93-100. doi: 10.3109/00365521.2012.746389. Epub 2012 Dec 3.
5
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.欧洲肝脏研究学会-欧洲肿瘤内科学会临床实践指南：肝细胞癌的管理
J Hepatol. 2012 Apr;56(4):908-43. doi: 10.1016/j.jhep.2011.12.001.
6
Management of hepatocellular carcinoma: an update.肝细胞癌的管理：最新进展
Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199.
7
Detection of novel biomarkers of liver cirrhosis by proteomic analysis.通过蛋白质组学分析检测肝硬化的新型生物标志物。
Hepatology. 2009 Apr;49(4):1257-66. doi: 10.1002/hep.22764.
8
Exceeding the limits of liver histology markers.超出肝脏组织学标志物的限度。
J Hepatol. 2009 Jan;50(1):36-41. doi: 10.1016/j.jhep.2008.07.039. Epub 2008 Oct 18.
9
Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests.肝纤维化的生物标志物：分子发病机制的临床转化还是基于肝脏相关功能异常检测
Clin Chim Acta. 2007 Jun;381(2):107-13. doi: 10.1016/j.cca.2007.02.038. Epub 2007 Feb 27.
10
Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers.丙型肝炎病毒感染患者的肝硬化可以通过标准生化血清标志物指数来排除。
Scand J Gastroenterol. 2005 Jul;40(7):867-72. doi: 10.1080/00365520510015674.